Tell Your Dad - Armune BioScience

Transcription

Tell Your Dad - Armune BioScience
Tell Your DadSM
June is Men’s Health Month
Men need to be reminded about the importance of
early detection to treat serious diseases
Step-up!
Tell Your DadSM 3 important things about his health
Copyright © 2008-2015, Armune BioScience, Inc.
June is Men’s Health Month
Dads often get labeled as poor listeners at home.
Dads will listen to their daughters.
Daughters, it is time to Step-up
and Tell Your DadSM
3 important things for his health.
1
Tell Your DadSM About his risk for
Prostate Cancer1
• Prostate cancer is the #1 non-skin cancer among men.
• In 2015, the estimates for prostate cancer in the United States are:
■■
About 220,800 new cases of prostate cancer
■■
About 27,540 deaths from prostate cancer
• About 1 man in 7 will be diagnosed with prostate cancer during
his lifetime.
• African-American men are more than twice as likely to die of
prostate cancer as white men.
• Tell your dad to talk with his physician about his risk for prostate
cancer and determine if screening for prostate cancer is
appropriate for him.2
2
Tell Your DadSM About Apifiny™
• Apifiny is a cancer specific blood test that measures the body’s
immune system response to prostate cancer.
• Apifiny is the only cancer specific, non-PSA blood test available in
the world that may aid clinicians in the detection of prostate cancer.
Apifiny™ Prostate Cancer
Lower
Risk
0
59
Higher
Risk
100
Risk Assessment
3
Tell Your DadSM To ask his physician
if Apifiny™ is right for him
• Shared decision making
2
between your dad and his clinician is an
important part of his overall healthcare.
• If your dad has an elevated PSA (>2.5 ng/ml) and is considering a
prostate biopsy, Apifiny may help him and his clinician decide if a
biopsy is the most appropriate next step in his care.
• Make sure your dad is prepared to have a productive discussion
with his physician about his risk for prostate cancer.
1. www.cancer.org/cancer/prostatecancer
2. www.auanet.org/education/guidelines/prostate-cancer-detection
The only cancer specific, non-PSA blood test that may
aid clinicians in the detection of prostate cancer
Apifiny™ Prostate Cancer
0
Lower
Risk
59
Higher
Risk
100
Risk Assessment
Does your dad know his
Apifiny™ Score?
Armune BioScience, Inc.
401 West Morgan Road
Ann Arbor, MI 48108
Toll Free Helpline: 844-427-6863
www.armune.com
06/15

Similar documents

Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market

Prostate Cancer - Global Drug Forecast and Market Analysis to 2023 for the $8.2 Billion Market Prostate cancer market was valued at $2.6 billion in 2013 and it is expected to reach $8.3 million, by 2023. It is estimated that the market will grow at a CAGR of 12.4%. This growth will be driven by the label extensions of currently marketed drugs as well as the launch of nine new premium-priced therapies for the treatment of prostate cancer.

More information

Hormone Sensitive Prostate Cancer Market Segments, Opportunity, Growth and Forecast by End-use Industry 2016-2026

Hormone Sensitive Prostate Cancer Market Segments, Opportunity, Growth and Forecast by End-use Industry 2016-2026 Prostate cancer is a general term used for diseased condition in which abnormal cells grow and invade in uncontrolled manner in the prostate. Prostate cancer inhibits production of male sex hormones (i.e. androgens) and ultimately blocks the action of androgen. The androgen is also responsible for the growth of prostate cancer. Androgen binds with the receptors and stimulates the expression of specific genes that would be responsible for prostate cancer. However, androgen suppression hormonal therapies are commonly used for the treatment of this cancer. These therapies acts by reducing the production of androgen by the testicles or by blocking the action of androgen in the body. There is an opportunity for the growth of hormone sensitive prostate cancer owing to the rapidly aging population which is the major cause of prostate cancer.

More information